Nashik, Feb 04: The Union Budget 2026 marks a significant moment for Indian healthcare. For the first time in the history of independent India, the healthcare allocation has crossed the 1 lakh Cr mark registering nearly 10 per cent rise from revised estimates of FY 2025–26, which is truly a welcome and symbolic milestone. While the sector still needs much more, crossing this threshold signals a strong intent to prioritise health in the national agenda. The proposed investment of nearly Rs.10,000 Cr over the next five years in biopharmaceutical manufacturing presents a major opportunity for India to emerge as a global biopharma hub. Equally encouraging is the plan to expand the country’s clinical research ecosystem with over 1,000 accredited clinical trial sites, which will strengthen evidence-based medicine and innovation. The Government’s focus on expanding medical education by increasing MBBS and postgraduate seats, along with adding over one lakh allied healthcare professionals in the coming years, will go a long way in addressing the manpower gap in our healthcare system. The proposal to establish multiple Ayurveda-focused institutions on the lines of AIIMS also reflects a balanced and inclusive approach to healthcare development.

From an oncology perspective, the significant reduction in duties on 17 imported immunotherapy and cancer drugs is a very important step. This will help lower treatment costs, improve access to globally accepted standard therapies and ultimately contribute to better patient outcomes and survival. Overall, this is a positive and forward-looking healthcare budget. The real impact, however, will depend on effective and timely implementation. If executed well, these initiatives can meaningfully strengthen India’s healthcare ecosystem in the years to come.